The purpose of this study is to evaluate whether the addition of selexipag to standard of
care treatment delays disease progression in children with Pulmonary Arterial Hypertension
(PAH) in comparison to placebo.
The purpose of the study is to assess the effects of selexipag on right ventricular (RV)
function in participants with Pulmonary arterial hypertension (PAH).
The purpose of this study is to assess the long-term safety of selexipag while providing
continued selexipag treatment for participants who were previously enrolled in an
Actelion-sponsored study with selexipag and who derived benefit from selexipag in indications
for which a positive benefit-risk has been established.
The objectives of this study are to evaluate the efficacy and safety of sotatercept treatment
(plus background PAH therapy) versus placebo (plus background PAH therapy) at 24 weeks in
adults with PAH.
This is a two-part (Phase 2/Phase 3) study of MK-5475, an inhaled soluble guanylate cyclase
stimulator, in participants with pulmonary arterial hypertension (PAH).
The first part (Phase 2) will assess three different doses of MK-5475 compared to placebo;
the treatment dose with the best efficacy and safety profile will be selected for use in the
second part (Phase 3) of the study. The primary hypothesis of Phase 2 is that at least one
MK-5475 dose group is superior to placebo in reducing pulmonary vascular resistance (PVR)
from baseline at week 12.
The purpose of the second part (Phase 3) of the study is to confirm the efficacy,...
A randomized, double-blind, placebo-controlled dose escalation and verification study to
assess the safety and efficacy of pulsed inhaled nitric oxide (iNO) in subjects at risk for
pulmonary hypertension associated with pulmonary fibrosis on long term oxygen therapy (Part 1
and Part 2) - REBUILD
This is a prospective, multicenter, open-label, randomized, controlled, parallel group,
group-sequential, event-driven Phase 3 study to evaluate efficacy, safety and
pharmacokinetics (PK) of macitentan in children.
The purpose of the study is to evaluate the effect of macitentan 75 mg versus placebo on
exercise capacity at Week 28 in participants with chronic thromboembolic pulmonary
This is an open-label, multicentre study evaluating the effect, safety and tolerability of
the two regio isomers 1-(nitrosooxy)propan-2-ol and 2- (nitrosooxy)propan-1-ol (PDNO)
infusion given to COVID-19 patients with acute pulmonary hypertension (aPH).
Selexipag is available in many countries for the treatment of pulmonary arterial hypertension
(PAH). Due to the similarities between PAH and chronic thromboembolic pulmonary hypertension
(CTEPH) and the observed efficacy of other PAH medicines in CTEPH, it is believed that
selexipag could benefit to patients with CTEPH. This study aims to assess the efficacy and
safety of selexipag in subjects with inoperable or persistent/recurrent CTEPH.